Evidence map›Paper›PMID 27730361›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2017

Multifocal cognitive dysfunction in high-dose benzodiazepine users: a cross-sectional study.

Angela Federico, Stefano Tamburin, Alice Maier, Marco Faccini, Rebecca Casari, Laura Morbioli, Fabio Lugoboni

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Benzodiazepine high-doses: The need for an accurate definition.International journal of methods in psychiatric research · 2021
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Towards a Redefinition of Cognitive Frailty.Journal of Alzheimer's disease : JAD · 2020
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Rare Diseases Day and Brain Awareness Week: the active participation of Neurological Sciences.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Angela FedericoDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Piazzale Scuro 10, 37134, Verona, Italy.
Stefano TamburinDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Piazzale Scuro 10, 37134, Verona, Italy. stefano.tamburin@univr.it.ORCID http://orcid.org/0000-0002-1561-2187
Alice MaierDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Piazzale Scuro 10, 37134, Verona, Italy.
Marco FacciniDepartment of Internal Medicine, Addiction Unit, Verona University Hospital, Piazzale Scuro 10, 37134, Verona, Italy.
Rebecca CasariDepartment of Internal Medicine, Addiction Unit, Verona University Hospital, Piazzale Scuro 10, 37134, Verona, Italy.
Laura MorbioliDepartment of Internal Medicine, Addiction Unit, Verona University Hospital, Piazzale Scuro 10, 37134, Verona, Italy.
Fabio LugoboniDepartment of Internal Medicine, Addiction Unit, Verona University Hospital, Piazzale Scuro 10, 37134, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benzodiazepines (BZDs) are the most widely prescribed drug class in developed countries, but they have high potential for tolerance, dependence and abuse. Cognitive deficits in long-term BZD users have long been known, but previous results might have been biased by patients' old age, coexisting neurological or psychiatric conditions or concurrent alcohol or psychotropic drug dependence. The study was aimed to explore the neuropsychological effect of high-dose BZD dependence, which represents an emerging addiction phenomenon. We recruited a group of high-dose BZD users with neither neurological or psychiatric comorbidity except anxiety or depression nor concurrent alcohol or psychotropic drug dependence. They underwent a battery of cognitive tests to explore verbal, visuospatial memory, working memory, attention, and executive functions. All the neuropsychological measures were significantly worse in patients than controls, and some of them were influenced by the BZD cumulative dose. The severity of depression and anxiety had a minimal influence on cognitive tests. Patients with high-dose BZD intake show profound changes in cognitive function. The impact of cognition should be considered in this population of patients, who may be involved in risky activities or have high work responsibilities.

Indexed as

BenzodiazepinesAdultAgedAttentionCognitionCognitive DysfunctionCross-Sectional StudiesExecutive FunctionFemaleHumansMaleMemory, Short-TermMiddle AgedNeuropsychological TestsSubstance-Related DisordersBenzodiazepinesAttentionBenzodiazepineClinical neuropsychologyDrug abuseExecutive functionsMemory

Identifiers

PMID27730361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.